Parkinson’s disease (PD) is an age associated neurodegenerative disorder. So far, no
therapeutic approach for the inhibition of disease progression has been described. We
recently described a new use for a small molecule drug with the potential to modify the
progression of PD and thereby to act therapeutic. Here we aim at further development of this
drug and explore the potential acceptance of the market for this approach.